Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Bernard J. Escudier, Camillo Porta, Manuela Schmidinger et al. · Annals of Oncology · 2019
Cited by 1,148 works. doi:10.1093/annonc/mdz056 Open-access PDF
Authors
- Bernard J. Escudier
- Camillo Porta
- Manuela Schmidinger
- Nathalie C. Rioux-Leclercq
- Axel Bex
- Vincent S Khoo
- Viktor Grünwald
- Silke Gillessen
- Alan Horwich
References
- Cancer statistics, 2016
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
- Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial